Showing 4311-4320 of 5957 results for "".
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- Visionix Unveils Second Generation VX 650 Multimodal Screener at Vision Expo 2023https://modernod.com/news/visionix-unveils-second-generation-vx-650-multimodal-screener-at-vision-expo-2023/2481461/Visionix announces a new multimodal device update with its second-generation VX 650. Launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging. The enhanced wavefront-based aberrometer's "quick mode" and new capture flexibilities can decrease screeni
- Sight Sciences Launches the Ergo-Series of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-launches-the-ergo-series-of-the-omni-surgical-system/2481457/Sight Sciences announced the US launch of the Ergo-Series of the OMNI Surgical System, a technology designed to facilitate surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. The OMNI Sur
- Pioneers in Retinal Gene Therapies Awarded International Harrington Prizehttps://modernod.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/The tenth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania;
- NIH: Eye Experts Weigh In on Artificial Tears in Midst of Infectious Outbreakhttps://modernod.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/The Centers for Disease Control and Prevention (CDC) is investigating how the virulent strain of P. aeruginosa ended up in EzriCare and Delsam Pharma artificial tears. According to an
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- J&J Vision Receives CE Mark Approval for the ELITA Femtosecond Laser Systemhttps://modernod.com/news/jj-vision-receives-ce-mark-approval-for-the-elita-femtosecond-laser-system/2481440/Johnson & Johnson Vision has received CE Mark approval for the ELITA Femtosecond Laser System for laser vision correction. The new laser will allow surgeons to perform refractive correction on patients with myopia, with or without astigmatism, via a new lenticular procedure called t
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- Aflibercept 8 mg BLA for Treatment of Wet AMD and DME Accepted for FDA Priority Reviewhttps://modernod.com/news/aflibercept-8-mg-bla-for-treatment-of-wet-amd-and-dme-accepted-for-fda-priority-review/2481433/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review the Biologics License Application (BLA) for aflibercept 8 mg for treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. The FDA t
- CDC Expands Recall of OTC Artificial Tearshttps://modernod.com/news/cdc-expands-recall-of-otc-artificial-tears/2481430/After reports of additional infections, the Centers for Disease Control and Prevention (CDC) has expanded its recall of OTC eye drops to include Delsam Pharma’s Artificial Tears products. The call for immediate discontinuation comes a month after the agency recommended immediate discontinua